By Xiaoban Xin ( June 30, 2026, 3:20 PM EDT) -- Antibody-drug conjugates, or ADCs, often described as magic bullets, have become a major focus of biopharmaceutical innovation due to their ability to combine targeted delivery with potent cytotoxic effects. Satisfying the written description and enablement requirements has emerged as a significant challenge in patenting ADC inventions in the U.S....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.